These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23322007)

  • 21. Innovative vaccine production technologies: the evolution and value of vaccine production technologies.
    Bae K; Choi J; Jang Y; Ahn S; Hur B
    Arch Pharm Res; 2009 Apr; 32(4):465-80. PubMed ID: 19407962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intellectual property rights and challenges for development of affordable human papillomavirus, rotavirus and pneumococcal vaccines: Patent landscaping and perspectives of developing country vaccine manufacturers.
    Chandrasekharan S; Amin T; Kim J; Furrer E; Matterson AC; Schwalbe N; Nguyen A
    Vaccine; 2015 Nov; 33(46):6366-70. PubMed ID: 26368398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Annual World Vaccine Congress 2014: a re-evaluation of the value proposition for increasing vaccine thermostability.
    Derwand R
    Hum Vaccin Immunother; 2014; 10(10):3087-9. PubMed ID: 25483655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chinese vaccine products go global: vaccine development and quality control.
    Xu M; Liang Z; Xu Y; Wang J
    Expert Rev Vaccines; 2015 May; 14(5):763-73. PubMed ID: 25697690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The U.S. vaccine and immunization enterprise: Working to sustain and foster vaccine innovation.
    Shen AK
    Hum Vaccin; 2009 Oct; 5(10):649-53. PubMed ID: 19713758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An analysis of how the GAVI alliance and low- and middle-income countries can share costs of new vaccines.
    Saxenian H; Cornejo S; Thorien K; Hecht R; Schwalbe N
    Health Aff (Millwood); 2011 Jun; 30(6):1122-33. PubMed ID: 21653966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The current challenges for vaccine development.
    Oyston P; Robinson K
    J Med Microbiol; 2012 Jul; 61(Pt 7):889-894. PubMed ID: 22322337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccines, our shared responsibility.
    Pagliusi S; Jain R; Suri RK;
    Vaccine; 2015 May; 33(19):2197-2202. PubMed ID: 25749248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The future of pharmaceutical manufacturing in the context of the scientific, social, technological and economic evolution.
    Stegemann S
    Eur J Pharm Sci; 2016 Jul; 90():8-13. PubMed ID: 26542345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influenza vaccine innovation system and lessons for PDPs.
    Huzair F
    Hum Vaccin Immunother; 2012 Mar; 8(3):407-10. PubMed ID: 22327495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Addressing supply side barriers to introduction of new vaccines to the developing world.
    McElligott S
    Am J Law Med; 2009; 35(2-3):415-41. PubMed ID: 19697757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human capital gaps in vaccine development: an issue for global vaccine development and global health.
    Cawein A; Emini E; Watson M; Dailey J; Donnelly J; Tresnan D; Evans T; Plotkin S; Gruber W
    Ann N Y Acad Sci; 2017 May; 1395(1):3-11. PubMed ID: 28229472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Down on the "pharm": do genetically modified plants hold the key to cheaper drugs?
    Watts G
    BMJ; 2012 May; 344():e3829. PubMed ID: 22654068
    [No Abstract]   [Full Text] [Related]  

  • 34. Donors agree financial arrangement to stimulate vaccine development.
    Jack A
    BMJ; 2008 Apr; 336(7648):797. PubMed ID: 18403540
    [No Abstract]   [Full Text] [Related]  

  • 35. A review of reverse vaccinology approaches for the development of vaccines against ticks and tick borne diseases.
    Lew-Tabor AE; Rodriguez Valle M
    Ticks Tick Borne Dis; 2016 Jun; 7(4):573-85. PubMed ID: 26723274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. European strategy for vaccine development against infectious diseases.
    Matthiessen L; Lång H; Klimathianaki M; Hanrahan F; Kerstiëns B; Martini A; Draghia-Akli R
    Vaccine; 2017 Jan; 35 Suppl 1():A20-A23. PubMed ID: 28017443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Developing vaccines for an aging population.
    Black S; De Gregorio E; Rappuoli R
    Sci Transl Med; 2015 Apr; 7(281):281ps8. PubMed ID: 25834107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Children's Vaccine Initiative and vaccine supply: the role of the public sector.
    van Noort RB
    Vaccine; 1992; 10(13):909-10. PubMed ID: 1471410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and technology transfer of Haemophilus influenzae type b conjugate vaccines for developing countries.
    Beurret M; Hamidi A; Kreeftenberg H
    Vaccine; 2012 Jul; 30(33):4897-906. PubMed ID: 22683521
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.